There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD73


CD73 Molecule Information

Target Synonym:5 -nucleotidase;NT5E;Ecto-5 -nucleotidase;CD_antigen=CD73;5 -NT;NT5 ;NTE
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Phase ?

CD73 Protein Product ListCompare or Buy

CD73 Part of Bioactivity data


Anti-CD73 antibody (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD73, His Tag (HPLC-verified) (Cat. No. CD3-H52H7) with an affinity constant of 0.164 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).


Loaded Anti-CD73 MAb (Human IgG1) on AHC Biosensor, can bind Human CD73, His Tag (HPLC-verified) (Cat. No. CD3-H52H7) with an affinity constant of 0.179 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD73 Molecule Synonym Name


CD73 Molecule Background

5'-nucleotidase also known as NT5E, CD73,

CD73 References

CD73 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CPI-006 CPI-006 Phase Ⅰ Corvus Triple negative breast cancer, Non small cell lung cancer (NSCLC), Renal cell carcinoma, Endometrial cancer, Squamous cell carcinoma of head and neck cancer (SCCHN), Colorectal cancer, Metastatic castration-resistant prostate cancer (mCRPC), Sarcoma, Bladder cancer, Ovarian cancer, Cervical carcinoma, Pancreatic cancer Details
Anti-CD73 monoclonal antibody (Bristol-Myers Squibb) Phase Ⅰ Bristol-Myers Squibb Cancer Details
TJ-004309 TJD-5; TJ-004309; TJ-4309 Phase Ⅱ I-MAB Biopharma, Tracon Pharma Solid tumours, Metastatic cancer Details
LY-3475070 LY-3475070 Phase Ⅰ Lilly Cancer Details
BMS-986179 BMS-986179 Phase Ⅱ Bristol-Myers Squibb Solid tumours Details
Oleclumab MEDI-9447 Phase Ⅱ MedImmune Non small cell lung cancer (NSCLC), Prostate cancer, Breast cancer, Ovarian cancer, Pancreatic cancer Details
AB-680 AB-680 Phase Ⅱ Arcus Biosciences Castration-resistant prostate cancer (CRPC) Details
SRF-373 SRF-373; NZV-930 Phase Ⅰ Surface Oncology, Novartis Solid tumours Details

This web search service is supported by Google Inc.